Key Takeaways
- MAIA Biotechnology reports promising results from its THIO-101 trial for advanced non-small cell lung cancer (NSCLC).
- Median overall survival for patients receiving THIO treatment is 16.9 months, significantly higher than standard chemotherapy.
- Potential for accelerated FDA approval as the trial progresses and further results become available.
Positive Trial Data Announced
MAIA Biotechnology, Inc. has released updated data from its pivotal Phase 2 clinical trial, THIO-101, focused on its lead candidate, THIO, combined with Regeneron’s immune checkpoint inhibitor, cemiplimab (Libtayo®). This trial targets patients with advanced non-small cell lung cancer (NSCLC) who have not responded to at least two previous treatment regimens.
As of January 15, 2025, the trial’s results indicated a median overall survival (OS) of 16.9 months for 22 NSCLC patients who received at least one dose of THIO. This outcome comes with a 95% confidence interval lower bound of 12.5 months and a 99% confidence interval lower bound of 10.8 months. These findings stand in stark contrast to standard chemotherapy treatments, which typically offer an OS of only 5 to 6 months.
Dr. Vlad Vitoc, CEO of MAIA, highlighted the results, stating, “THIO’s efficacy in advanced stages of NSCLC continues to exceed our expectations, especially in third-line treatment.” The company believes THIO has the potential to fill a significant gap in treatment for patients facing limited options.
Furthermore, MAIA is optimistic about the regulatory pathway for THIO, suggesting there could be an opportunity for accelerated FDA approval based on developments in the ongoing trial. THIO, a first-in-class telomere-targeting agent, works by disrupting the survival mechanisms of cancer cells, making them more vulnerable to treatment.
The THIO-101 trial is multicenter, open-label, and aims to assess THIO’s safety and efficacy, particularly in patients who have previously resisted other forms of treatment. By evaluating the drug’s anti-tumor activity when combined with PD-(L)1 inhibitors like cemiplimab, the trial seeks to enhance immune response in resistant cases.
As the trial progresses, MAIA is committed to providing updates and further insights into the potential benefits of THIO for patients with significant unmet medical needs. For more detailed information on the study, interested parties can visit ClinicalTrials.gov using the identifier NCT05208944.
MAIA Biotechnology remains focused on developing innovative therapies aimed at improving survival rates for cancer patients, reinforcing its commitment to advancing healthcare solutions that address critical gaps in current treatment modalities.
The content above is a summary. For more details, see the source article.